MAO-B-IN-45
MAO-B-IN-45 is a dual inhibitor of ferroptosis and MAO-B. MAO-B-IN-45 shows selectivity towards MAO-B with an IC50 of 87.47 nM and selectivity exceeding 229-fold for MAO-B over MAO-A. MAO-B-IN-45 has excellent antiferroptosis activity through modulation of the iron metabolic pathway and GSH-GPX4 axis in vitro. MAO-B-IN-45 improves cognitive and behavioral impairments in 3×Tg (APP/Tau/Ps1) AD mouse and significantly reduced the levels of ferritin heavy chain 1 (FTH1), APP, and Tau phosphorylation (p-Tau) proteins in the brain.
For research use only. We do not sell to patients.
- CAS No.: 3069915-36-9
- Formula: C17H14ClNO3
- Molecular Weight:315.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
GPX4 |
hMAO-B 87.47 nM (IC50) |
In Vitro
MAO-B-IN-45 (compound 21d) is a reversible hMAO-B inhibitor with inhibition constant a Ki value of 100.6 nM , which displays high hMAO-B inhibitory activity, and the inhibition rate are 94.81% (10 μM) and 76.31% (1 μM)[1].
MAO-B-IN-45 (0.1-75 μM, 24 h) shows favorable safety in PC12 cells and HT22 cells[1].
MAO-B-IN-45 (1-50 μM, 24 h) effectively mitigates ferroptosis induced by RSL3 (HY-100218A) or Erastin (HY-15763) in a dose-dependent manner in HT22 cells[1].
MAO-B-IN-45 (10-50 μM, 24 h) reduces intracellular ROS production in HT22 cells[1].
MAO-B-IN-45 (15-100 μM, 24 h) effectively suppresses ferroptosis by both reducing intracellular iron accumulation and enhancing the GSH dependent pathway in HT22 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT22 cells, PC12 cells
-
Concentration:25, 50, and 75 μM (HT22 cells), 0.1, 1, 10, 20, 30, 40, 50, 75 μM (PC12 cells)
-
Incubation Time:24 h
-
Result:Showed favorable safety, maintaining a cell viability of 83.56% on PC12 cells and 86.47% on HT22 cells at the highest test concentration (75 μM), warranting further investigation.
-
Cell Line:RSL3/Erastin-induced HT22 cells
-
Concentration:1, 5, 10, 25, 50 μM
-
Incubation Time:24 h
-
Result:Reduced ferroptosis induced by RSL3 and Erastin at a concentration of 10 μM and completely restored cell viability to normal levels at 50 μM.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Triple-transgenic (APP/Tau/Ps1) mice (30-35 g, 7 months)[1].
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection daily for 35 days
-
Result:Increased the number of entries, and reduced the latency and distance to the platform, showing effects comparable to those observed in the safinamide and donepezil groups.
Not markedly different from wild-type mice in cognitive function.
No abnormalities in the tissues (heart, liver, spleen, lung, kidney) compared to those of wild type mice (H&E staining).
Normalized FTH1 levels in 3×Tg mice, and significantly increased the expression level of GPX4.
Reduced the protein level of APP, and decreased the site-specificity in p-Tau at Ser202/Thr205.
Chemical Information
-
CAS No. 3069915-36-9
-
Molecular Weight 315.75
-
Formula C17H14ClNO3
-
SMILES
CN1C(C(O)=CC2=CC=C(C=C21)OCC3=CC=C(C=C3)Cl)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)